Investor Relations

Investor Relations

Overview

Chemomab is a clinical-stage biopharmaceutical company, focusing on discovery and development of innovative therapeutics for fibrosis-related diseases with large unmet need.

The company’s lead candidate, CM-101, is a first-in-class monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action.

Chemomab is currently testing CM-101 in three phase 2 studies focusing on the rare indications primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc)

Recent News
Jun 10, 2021

Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need,...

May 13, 2021

Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need,...

May 12, 2021

Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need,...

Apr 26, 2021

Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need,...

all news

Stock Info
NASDAQCMMB
Featured Presentation

Chemomab Corporate Overview - May 2021

download PDF